Increased levels of total oxidant status and decreased activity of arylesterase in migraineurs

Clinical Biochemistry

Volumn 44, Issue 10-11, 2011, Pages 832-837

  Yilmaz, Necat ^a   Aydin, Ozgur ^a   Yegin, Aysenur ^a   Tiltak, Aysun ^a   Eren, Esin ^a  

^a MINISTRY OF HEALTH   (Turkey)

Author keywords

Antioxidant; Arylesterase; Migraine; Oxidant; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DEMOGRAPHY; EPILEPSY; FEMALE; FIBRINOGEN; HUMANS; LIPIDS; MALE; MIGRAINE DISORDERS; OXIDANTS;

EID: 79958826391     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.04.015     Document Type: Article

References (36)

1. Rasmussen B.K. Epidemiology of headache. Cephalalgia 2001, 21:774-777.
2. Lance J. Current concepts of migraine pathogenesis. Neurology 1993, 43:11-15.
3. Gruber H.J., Bernecker C., Lechner A., Weiss S., Wallner-Blazek M., Meinitzer A., Höbarth G., Renner W., Fauler G., Horejsi R., Fazekas F., Truschnig-Wilders M. Increased nitric oxide stress is associated with migraine. Cephalalgia 2010, 30:486-492.
4. Yilmaz G., Surer H., Inan L.E., Coskun O., Yucel D. Increased nitrosative and oxidative stress in platelets of migraine patients, Tohoku. J Exp Med 2007, 211:23-30.
5. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004, 84:1381-1478.
6. Sobainec W., Solowiej E., Kulak W., Bockowski L., Smigielska-Kuiza J., Artemowicz B. Evaluation of the influence of antiepileptic therapy on antioxidant enzyme activity and lipid peroxidation in erythrocytes of children with epilepsy. Child Neurol 2006, 21:558-562.
7. Bigal M.E., Kurth T., Santanello N., Buse D., Golden W., Robbins M., Lipton R.B. Migraine and cardiovascular disease: a population-based study. Neurology 2010, 74:628-635.
8. Sas K., Pardutz A., Toldi J., Vecsei L. Dementia, stroke and migraine-some common pathological mechanisms. J Neurol Sci 2010, Epub ahead of print.
9. Gaillard T., Parthasarathy S., Osei K. HDL dysfunctionality (paraoxonase) is worse in nondiabetic, postmenopausal African American than in white women. Diabetes Care 2011, 3(4):e19.
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parma S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
11. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalysing both activities. Drug Metab Dispos 1991, 19:100-106.
12. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
13. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation more stable ABTS radical cation. Clin Biochem 2004, 37:277-285.
14. Harma M., Harma M., Erel O. Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly 2003, 133:563-566.
15. Garcia-Martin E., Martinez C., Serrador M., Alonso-Navarro H., Navacerrada F., Agundez J.A., Jimenez F.J. Paraoxonase 1 (PON1) polymorphisms and risk for migraine. J Neurol 2010, 257:1482-1485.
16. The international classification of headache disorders. Cephalalgia 2004, 24 Suppl. 1:9-160. Headache Classification Subcomittee of International Headache Society. 2nd edition.
17. Eckerson H.W., Wyte M.C., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
18. Haagen L., Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolisis of 4-nitrophenyl acetate. Eur J Clin Chem Clin Biochem 1992, 30:391-395.
19. Kosecik M., Erel O., Sevinc E., Selek S. Increased oxidative stress in children exposed to passive smoking. Int J Cardiol 2005, 100:61-64.
20. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005, 38:153-163.
21. Gaidukov L., Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA-I. Biochemistry 2005, 44:11843-11854.
22. Graves T.L., Scott J.E. A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity. Curr Chem Genomics 2008, 2:51-61.
23. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1(PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006, 281:7657-7665.
24. Otocka-Kmiecik A., Orłowska-Majdak M. The role of genetic (PON1 polymorphism) and environmental factors, especially physical activity, in antioxidant function of paraoxonase. Postepy Hig Med Dosw 2009, 63:668-677.
25. Ciancarelli I., Tozzi-Ciancarelli M.G., Di Massimo C., Marini C., Carolei A. Flunarizine effects on oxidative stress in migraine patients. Cephalalgia 2004, 4:28-32.
26. Ciancarelli I., Tozzi-Ciancarelli M.G., Di Massimo C., Marini C., Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine. Cephalalgia 2003, 23:39-42.
27. Boćkowski L., Sobaniec W., Kułak W., Smigielska-Kuzia J. Serum and intraerythrocyte antioxidant enzymes and lipid peroxides in children with migraine. Pharmacol Rep 2008, 60:542-548.
28. Taffi R., Vignini A., Lanciotti C., Luconi R., Nanetti L., Mazzanti L., Provinciali L., Silvestrini M., Bartolini M. Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods. Cephalalgia 2005, 25:353-358.
29. Ciancarelli I., Tozzi-Ciancarelli M.G., Spacca G., Di Massimo C., Carolei A. Relationship between biofeedback and oxidative stress in patients with chronic migraine. Cephalalgia 2007, 27:1136-1141.
30. Bigal M.E. Migraine, lipid profile, and cardiovascular disease. Eur J Neurol 2010, 17:342-343.
31. Bigal M.E., Lipton R.B., Biondi D.M., Xiang J., Hulihan J. Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine. Cephalalgia 2009, 29:1188-1196.
32. Gruber H., Bernecker C., Pailer S., Lechner A., Horejsi R., Möller R., Fazekas F., Truschnig-Wilders M. Lipid profile in normal weight migraineurs-evidence for cardiovascular risk. Eur J Neurol 2010, 17:419-425.
33. Monastero R., Pipia C., Cefalu A.B., Liveri E.T., Rosano R., Camarda R., Camarda C. Association between plasma lipid levels and migraine in subjects aged>or=50years: preliminary data from Zabut Aging Project. Neurol Sci 2008, 29:179-181.
34. Kurth T., Ridker P.M., Buring J.E. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 2008, 28:49-56.
35. Hofer S.E., Bennetts B., Chan A.K., Holloway B., Karschimkus C., Jenkins A.J., Silink M., Donaghue K.C. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications 2006, 20:322-328.
36. Mackness M.I., Durrington P.N., Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000, 11:383-388.